Comorbidity of hypertension and lung cancer: interplay of genetics and environment

Abstract Hypertension and lung cancer are two of the most prevalent chronic diseases worldwide, each contributing significantly to public health burdens. While both diseases have been extensively studied individually, their comorbidity remains an underexplored area of research. Recent studies sugges...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingtong Zeng, Difang Shi, Daqian He, Wenxun Dong, Zhenghong Yang, Ying Chen
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-03323-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343515197177856
author Jingtong Zeng
Difang Shi
Daqian He
Wenxun Dong
Zhenghong Yang
Ying Chen
author_facet Jingtong Zeng
Difang Shi
Daqian He
Wenxun Dong
Zhenghong Yang
Ying Chen
author_sort Jingtong Zeng
collection DOAJ
description Abstract Hypertension and lung cancer are two of the most prevalent chronic diseases worldwide, each contributing significantly to public health burdens. While both diseases have been extensively studied individually, their comorbidity remains an underexplored area of research. Recent studies suggest that genetic susceptibility plays a crucial role in the coexistence of these conditions, with overlapping genetic variants influencing both vascular homeostasis and tumorigenesis. The relationship between hypertension and lung cancer is complex, with shared risk factors and common pathogenic mechanisms, including inflammation, oxidative stress, and metabolic dysregulation. Environmental exposures—such as air pollution, tobacco smoke, and heavy metals—can trigger these genetic and epigenetic alterations, thereby increasing susceptibility to both conditions. Beyond genetic predisposition, epigenetic modifications significantly contribute to disease pathogenesis, including DNA methylation, histone modifications, and microRNA (miRNA) regulation. In hypertension, aberrant DNA methylation affects genes involved in vascular remodeling, such as At1b and Scnn1a, influencing blood pressure regulation. Similarly, in lung cancer, tumor suppressor genes such as p16, RASSF1A, and KCNK3 undergo methylation-induced silencing, promoting tumor progression. Histone modifications, particularly histone deacetylase (HDAC) activity, play a key role in both diseases, with HDAC inhibitors like valproic acid showing therapeutic potential in lowering blood pressure and inhibiting lung cancer cell proliferation. Understanding the shared genetic and epigenetic mechanisms between hypertension and lung cancer offers new opportunities for risk prediction, early intervention, and targeted therapies. Future research should focus on integrating genetic screening with environmental risk assessment to develop precision medicine strategies for individuals at high risk of both conditions.
format Article
id doaj-art-22f0ab87f9b6436f8ad194ced5a85dfb
institution Kabale University
issn 2730-6011
language English
publishDate 2025-08-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-22f0ab87f9b6436f8ad194ced5a85dfb2025-08-20T03:42:57ZengSpringerDiscover Oncology2730-60112025-08-0116113510.1007/s12672-025-03323-3Comorbidity of hypertension and lung cancer: interplay of genetics and environmentJingtong Zeng0Difang Shi1Daqian He2Wenxun Dong3Zhenghong Yang4Ying Chen5Department of Thoracic Surgery I, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital YunnanDepartment of Thoracic Surgery I, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital YunnanDepartment of Thoracic Surgery I, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital YunnanDepartment of Thoracic Surgery I, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital YunnanDepartment of Thoracic Surgery I, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital YunnanDepartment of Thoracic Surgery I, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital YunnanAbstract Hypertension and lung cancer are two of the most prevalent chronic diseases worldwide, each contributing significantly to public health burdens. While both diseases have been extensively studied individually, their comorbidity remains an underexplored area of research. Recent studies suggest that genetic susceptibility plays a crucial role in the coexistence of these conditions, with overlapping genetic variants influencing both vascular homeostasis and tumorigenesis. The relationship between hypertension and lung cancer is complex, with shared risk factors and common pathogenic mechanisms, including inflammation, oxidative stress, and metabolic dysregulation. Environmental exposures—such as air pollution, tobacco smoke, and heavy metals—can trigger these genetic and epigenetic alterations, thereby increasing susceptibility to both conditions. Beyond genetic predisposition, epigenetic modifications significantly contribute to disease pathogenesis, including DNA methylation, histone modifications, and microRNA (miRNA) regulation. In hypertension, aberrant DNA methylation affects genes involved in vascular remodeling, such as At1b and Scnn1a, influencing blood pressure regulation. Similarly, in lung cancer, tumor suppressor genes such as p16, RASSF1A, and KCNK3 undergo methylation-induced silencing, promoting tumor progression. Histone modifications, particularly histone deacetylase (HDAC) activity, play a key role in both diseases, with HDAC inhibitors like valproic acid showing therapeutic potential in lowering blood pressure and inhibiting lung cancer cell proliferation. Understanding the shared genetic and epigenetic mechanisms between hypertension and lung cancer offers new opportunities for risk prediction, early intervention, and targeted therapies. Future research should focus on integrating genetic screening with environmental risk assessment to develop precision medicine strategies for individuals at high risk of both conditions.https://doi.org/10.1007/s12672-025-03323-3HypertensionLung cancerInheritanceEnvironmentInteractions
spellingShingle Jingtong Zeng
Difang Shi
Daqian He
Wenxun Dong
Zhenghong Yang
Ying Chen
Comorbidity of hypertension and lung cancer: interplay of genetics and environment
Discover Oncology
Hypertension
Lung cancer
Inheritance
Environment
Interactions
title Comorbidity of hypertension and lung cancer: interplay of genetics and environment
title_full Comorbidity of hypertension and lung cancer: interplay of genetics and environment
title_fullStr Comorbidity of hypertension and lung cancer: interplay of genetics and environment
title_full_unstemmed Comorbidity of hypertension and lung cancer: interplay of genetics and environment
title_short Comorbidity of hypertension and lung cancer: interplay of genetics and environment
title_sort comorbidity of hypertension and lung cancer interplay of genetics and environment
topic Hypertension
Lung cancer
Inheritance
Environment
Interactions
url https://doi.org/10.1007/s12672-025-03323-3
work_keys_str_mv AT jingtongzeng comorbidityofhypertensionandlungcancerinterplayofgeneticsandenvironment
AT difangshi comorbidityofhypertensionandlungcancerinterplayofgeneticsandenvironment
AT daqianhe comorbidityofhypertensionandlungcancerinterplayofgeneticsandenvironment
AT wenxundong comorbidityofhypertensionandlungcancerinterplayofgeneticsandenvironment
AT zhenghongyang comorbidityofhypertensionandlungcancerinterplayofgeneticsandenvironment
AT yingchen comorbidityofhypertensionandlungcancerinterplayofgeneticsandenvironment